Switching from Mirtazapine 15 mg to Low-Dose Doxepin for Sleep
Gradually taper mirtazapine by 10-25% weekly while simultaneously starting low-dose doxepin 3-6 mg at bedtime, as both medications are sedating antidepressants with different mechanisms and can be safely overlapped during the transition.
Rationale for the Switch
The 2017 American Academy of Sleep Medicine guidelines specifically recommend low-dose doxepin (3-6 mg) for sleep maintenance insomnia, while noting that mirtazapine's efficacy for insomnia is not well established 1. Low-dose doxepin has FDA approval for insomnia and demonstrates consistent efficacy in improving wake after sleep onset and total sleep time 2. In contrast, mirtazapine at 15 mg is used off-label for sleep, lacks robust evidence for this indication, and carries concerns about weight gain and next-day sedation 3.
Specific Switching Protocol
Week 1-2: Initiate Cross-Taper
- Start doxepin 3 mg at bedtime (the recommended starting dose for insomnia) 1, 2
- Continue mirtazapine 15 mg
- Monitor for excessive sedation from overlapping medications
Week 2-3: Begin Mirtazapine Taper
- Reduce mirtazapine to 11.25 mg (25% reduction)
- Continue doxepin 3 mg
- This gradual reduction minimizes withdrawal symptoms including rebound insomnia, anxiety, and flu-like symptoms 4, 5
Week 3-4: Continue Taper
- Reduce mirtazapine to 7.5 mg
- If sleep remains inadequate, increase doxepin to 6 mg 2
Week 4-6: Complete Transition
- Reduce mirtazapine to 3.75 mg, then discontinue
- Maintain doxepin at effective dose (3-6 mg)
- The FDA label specifically warns against abrupt discontinuation of mirtazapine 4
Key Clinical Considerations
Doxepin dosing specifics: The therapeutic range for insomnia is 3-6 mg, which selectively antagonizes histamine H₁ receptors without significant anticholinergic effects at these low doses 6, 7, 8. This is vastly different from antidepressant dosing (25-300 mg).
Overlap safety: Both medications can be safely co-administered during the taper period. Unlike benzodiazepines or MAOIs, there are no contraindications to combining these sedating antidepressants at the doses used 3. However, monitor for additive sedation, particularly in elderly patients or those with hepatic impairment.
Withdrawal monitoring: Watch for mirtazapine withdrawal symptoms including insomnia rebound, irritability, nausea, dizziness, and anxiety 4, 5. If these emerge, slow the taper to 10% weekly reductions rather than 25% 9.
Common Pitfalls to Avoid
Do not stop mirtazapine abruptly - The FDA label explicitly warns against this, and withdrawal symptoms can be severe after chronic use 4
Do not use higher doses of doxepin - Doses above 6 mg increase anticholinergic side effects (dry mouth, constipation, urinary retention) without additional sleep benefit 6, 7
Do not extend the taper unnecessarily - A 4-6 week transition is appropriate for mirtazapine 15 mg used for sleep. Longer tapers (8-12 weeks) are only needed if the patient has been on higher doses (≥30 mg) or for longer duration (≥1 year) 9
Monitor for next-day residual effects - While low-dose doxepin has minimal next-day impairment in trials 6, 8, individual responses vary. Assess daytime functioning, particularly driving ability.
Evidence Quality Note
The 2020 VA/DoD guidelines and 2017 AASM guidelines provide the strongest evidence base, both recommending low-dose doxepin as a preferred pharmacologic option when behavioral interventions fail 2. The evidence for mirtazapine remains weak, with the 2008 AASM guideline noting that "efficacy for this indication is not well established" 3. The switching strategy outlined above follows general principles from the FDA labels and expert consensus on antidepressant transitions 4, 5, 9.